COVID Bivalent Booster Better vs Omicron Subvariants: Pfizer

Österreich Nachrichten Nachrichten

COVID Bivalent Booster Better vs Omicron Subvariants: Pfizer
Österreich Neuesten Nachrichten,Österreich Schlagzeilen
  • 📰 Medscape
  • ⏱ Reading Time:
  • 37 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 55%

One month after receiving a booster with the bivalent vaccine, those older than 55 had 4x more neutralizing antibodies against these Omicron subvariants compared with people who received the original monovalent vaccine as a booster in a recent study.

by the US Food and Drug Administration for ages 5 years and older. The safety and tolerability profile of the Pfizer/BioNTech bivalent booster remains favorable and similar to the original COVID-19 vaccine, the company reported.

"For example, there may be significant differences between the groups, and the release mentions at least one difference that is of importance: the interval since the last vaccination which often affects the response to subsequent boosting," she said. More researcher results are warranted."These data do not indicate that these differences between the two vaccines translate into a meaningful clinical benefit at a population level," El Sahly said."As we head into the holiday season, we hope these updated data will encourage people to seek out a COVID-19 bivalent booster as soon as they are eligible in order to maintain high levels of protection against the widely circulating Omicron BA.4 and BA.

Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen:

Medscape /  🏆 386. in US

Österreich Neuesten Nachrichten, Österreich Schlagzeilen

Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.

Pfizer-BioNTech booster targeting variants as safe as earlier COVID shots, 30-day data showsPfizer-BioNTech booster targeting variants as safe as earlier COVID shots, 30-day data showsPfizer and BioNTech have shown that their new bivalent COVID booster does what they hoped it would, with the same safety and side effect profile as earlier shots.
Weiterlesen »

Pfizer study says updated COVID boosters rev up protectionPfizer study says updated COVID boosters rev up protectionPfizer says its updated COVID-19 booster significantly revved up adults' virus-fighting antibodies.
Weiterlesen »

Pfizer-BioNTech bivalent booster shows higher immune response, but new COVID cases climb back above 40,000 a dayPfizer-BioNTech bivalent booster shows higher immune response, but new COVID cases climb back above 40,000 a dayUpdated trial data for Pfizer-BioNTech’s bivalent COVID booster showed a “substantially higher” immune response in adults than the original vaccine, the companies said.
Weiterlesen »

China posts 6-month high COVID count as it sticks with strategyChina posts 6-month high COVID count as it sticks with strategyChina on Sunday reported its highest number of new COVID-19 infections in six months, a day after health officials said they were sticking with strict coronavirus curbs, likely disappointing recent investor hopes for an easing.
Weiterlesen »



Render Time: 2025-03-09 04:39:01